[1] Gralnek IM, Neeman Z, Strate LL. Acute lower gastrointestinal bleeding[J]. N Engl J Med, 2017,376(11):1054-1063. DOI: 10.1056/NEJ Mcp1603455.
[2] Aoki T, Hirata Y, Yamada A, et al. Initial management for acute lower gastrointestinal bleeding[J]. World Journal of Gastroenterol, 2019,25(1):69-84. DOI: 10.3748/wjg. v25.i1.69.
[3] 中华医学会外科学分会结直肠肛门外科学组, 中华中医药学会肛肠病专业委员会, 中国中西医结合学会结直肠肛门病专业委员会. 痔临床诊治指南(2006版)[J]. 中华胃肠外科杂志,2006,9(5):461-463. DOI:10.3760/cma.j.issn.1671-0274. 2006.05.039.
[4] 胡伯虎,主编. 实用痔瘘学[M]. 第二版, 北京:科学技术文献出版社,1998: 106.
[5] Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence[J]. J Clin Epidemiol, 2011,64(4):401-406. DOI:10.1016/j.jclinepi. 2010.07.015.
[6] Yeo D, Tan KY. Hemorrhoidectomy-making sense of the surgical options[J]. World J Gastroenterol, 2014,20(45): 16976-16983. DOI: 10.3748/wjg.v20.i45.16976.
[7] 胡伯虎. 内痔注射疗法的历史回顾与进展[J]. 中国肛肠病杂志, 2018,38(12):72-73. DOI: 10.3969/j.issn.1000-1174. 2018.12.033.
[8] Zheng X, Wei QM, Zhang H. Novel developments in polidocanol sclerotherapy: a review[J]. J Biosciences Med, 2018,6:31-41. DOI: 10.1177/0 268355516687864.
[9] Pierluigi L, Rita L, Eugenio N, et al. Short-term results of sclerotherapy with 3% polidocanol foam for symptomatic second- and third-degree hemorrhoidal disease[J]. J Invest Surg, 2021,34(10):1059-1065. DOI: 10.1080/08941939. 2020.1745964.
[10] Nastasa V, Samaras K, Ampatzidis Ch,et al.Properties of polidocanol foam in view of its use in sclerotherapy[J]. Int J Pharm, 2015,478(2):588-596.DOI:10.1016/j.ijpharm. 2014. 11. 056.
[11] Vítor F, Jorge F. Polidocanol foam injected at high doses with intravenous needle: the (almost) perfect treatment of symptomatic internal hemorrhoids[J]. GE Portuguese J Gastroenterol, 2019,26(3):169-175. DOI: 10.1159/000 492202.
[12] Gaetano G, Arcangelo P, Renato P, et al. Sclerotherapy with 3% polidocanol foam to treat second-degree haemorrhoidal disease: 3-year follow-up of a multicentre, singlearm lDEAI phase 2b trial[J]. Colorectal Dis, 2023, 25(3):386-395. DOI: 10.1111/codi.16380.
[13] Toshihiko W, Michinobu O, Kazunori T. Efficacy and safety of sclerotherapy with polidocanol in children with internal hemorrhoids[J]. Pediatr Int, 2021,63(7):813-817. DOI: 10.1111/ped.14506.
[14] «结直肠肛门外科»杂志编辑委员会. 聚桂醇®内痔硬化注射疗法专家共识(2021版)[J].结直肠肛门外科, 2021,27(3):183-187.DOI:10.19668/j.cnki.issn1674-0491.2021. 03.001.
[15] 林子栋,席作武,赵斌,等.芍倍注射液治疗痔病研究进展[J].国医论坛,2023,38(2):75-78.
[16] 中国中西医结合学会大肠肛门疾病专业委员会. 痔芍倍注射疗法临床应用指南(2017版)[J].中华胃肠外科杂志,2017,20(12):1434-1436.DOI:10.3760/cma.j.issn.1671- 0274. 2017. 12.026.
[17] 王茜, 冯大勇, 白志勇, 等. 芍倍注射液治疗内痔的多中心临床分析[J]. 安徽中医药大学学报, 2018,37(6):21-24. DOI:10.3969/j.issn.2095-7246.2018.06.007.
[18] 史兆歧.消痔灵四步注射法治疗Ⅲ、Ⅳ期痔——闭塞直肠上动脉和痔硬化消失法[J]. 中国中西医结合杂志, 1998, 18(4): 201-203. DOI:10.3321/j.issn:1003-5370.1998.04.003.
[19] 张虹玺. 消痔灵注射疗法的临床应用研究[J]. 中国肛肠病杂志,2018,38(12):74-75. DOI:10.3969/j.issn.1000-1174. 2018.12.034.
[20] 李国栋,胡伯虎. 消痔灵注射疗法治疗内痔的诊疗规范(第二次审议稿)[J]. 中国肛肠病杂志, 2019,39(8):77-79. DOI:CNKI:SUN:GCBZ. 0.2019-08-038.
[21] 黄少鹏,叶庆华,李焕容,等. 消痔灵两步注射法在出血性痔中的应用[J]. 深圳中西医结合杂志, 2021, 31(13): 26-27. DOI:10.16458/j.cnki.1007-0893.2021.13. 012.
[22] 高有峰, 孙晓琴, 汤小秋. 消痔灵注射治疗混合痔术后继发性大出血20例效果观察[J]. 中国肛肠病杂志, 2019, 39(7): 49. DOI:10.3969/j.issn.1000-1174.2019.07. 026.
[23] 周丽华, 李威. 消痔灵分次注射治疗老年人Ⅰ期内痔出血的疗效观察[J]. 福建医药杂志, 2022, 44(4): 115-116,139. DOI:10.3969/j.issn.1002-2600.2022.04.039.
[24] 陈智强. 消痔灵注射治疗小儿直肠黏膜脱垂42例疗效观察[J]. 中国肛肠病杂志, 2019, 39(4): 37-38. DOI:10.3969/j.issn.1000-1174.2019.04.020.
[25] 陈琴, 李华山. 消痔灵问世40余载之国内外发展态势述评[J]. 江苏中医药, 2020, 52(7): 76-80. DOI:10.19844/j.cnki. 1672-397X.2020.07.027.
[26] 孙莉, 王军省. 消痔灵用于混合痔的临床进展[J]. 新疆中医药, 2020, 38(4): 79-81.
[27] Hidenori M, Takenori H, Gentaro I, et al. Aluminum potassium sulfate and tannic acid sclerotherapy for Goligher Grades II and III hemorrhoids: results from a multicenter study[J]. World J Hepatol, 2016,8(20):844. DOI: 10.4254/wjh.v8.i20.844.
[28] Lee YC, Shin HK, Lim CH, et al. Comparison of early clinical outcomes between ALTA(aluminum potassium sulfate and tannic acid,ziohn®) injection therapy and a submucosal hemorrhoidectomy in patients with internal hemorrhoids[J]. J Korean Soc Coloproctol, 2010, 26(3):179. DOI:10.3393/jksc.2010.26.3.179.
[29] Kheng-Seong Ng, Melanie Holzgang, Christopher Young. Still a case of 'No pain, no gain'? an updated and critical review of the pathogenesis, diagnosis, and management options for hemorrhoids in 2020[J]. Ann Coloproctol, 2020,36(3):133-147. DOI:10.3393/ac.2020.05. 04.
[30] 王汉涛,傅传刚,卢珊,等. 5%石炭酸麻油注射治疗内痔(附2450例报告)[J]. 中国实用外科杂志, 2001, 21(11): 660- 661. DOI:10.3321/j.issn:1005-2208.2001.11.011.
[31] Mustafa G, Asad A, Muntaha ST. Comparison of 5% phenol with almond oil versus 15% hypertonic saline in treatment of pediatric idiopathic rectal prolapse[J]. Cureus, 2022, 14(3):e23552. DOI:10.7759/cureus.23552.
[32] 应文辉. 50%葡萄糖溶液内痔注射的临床研究[J]. 浙江临床医学, 2000, 2(4):241-242. DOI:10.3969/j.issn.1008-7664. 2000.04.013.
[33] 唐宗娟,古世玲,崔洋. 50%葡萄糖混合液内痔注射加外剥内扎在混合痔患者中的临床效果及对生活质量的影响[J]. 中国医学创新, 2019,16(19):29-33.DOI:10.3969/j.issn.1674- 4985.2019.19.008.
[34] 覃尔松,黄耘. 50%葡萄糖注射液治疗二期内痔93例体会[J]. 中国乡村医药, 2009, 16(4): 26. DOI:10.3969/j.issn.1006- 5180.2009.04.019.
[35] 王亮锋,付海平,蒲万云,等. 50%葡萄糖和消痔灵注射液分别用于混合痔术中注射的疗效观察[J]. 黑龙江医药, 2020, 33(4): 863-864. DOI:10.14035/j.cnki.hljyy.2020.04.057.
[36] Gallo G, Martellucci J, Sturiale A, et al. Consensus statement of the Italian society of colorectal surgery (SICCR): management and treatment of hemorrhoidal disease[J]. Tech Coloproctol, 2020, 24(2):145-164. DOI: 10.1007/s10151-020-02149-1.
[37] Takashi O, Kazuko G, Shiro T, et al. Sclerosing effect of OC-108, a novel agent for hemorrhoids, is associated with granulomatous inflammation induced by aluminum[J]. J Pharmacol Sci, 2005, 99(4):353-363. DOI: 10.1254/jphs.fpj05026x.
[38] Takano M, Iwadare J, Ohba H, et al. Sclerosing therapy of internal hemorrhoids with a novel sclerosing agent. Comparison with ligation and excision[J]. Int J Colorectal Dis, 2006 21(1):44-51. DOI: 10.1007/s00384- 005-0771-0.
[39] Shunya T, Akira T, Tomoko T, et al. Early postoperative outcomes of a novel nonexcisional technique using aluminum potassium sulfate and tannic acid sclerotherapy with mucopexy on patients with grade III hemorrhoids[J]. Ann Coloproctol, 2022,38(4):290-296. DOI: 10.3393/ac.2020.00920.0131.
[40] Tetsuo Y. Japanese Practice Guidelines for Anal Disorders I. Hemorrhoids[J]. J Anus Rectum Colon, 2018,1(3):89- 99. DOI: 10.23922/jarc.2017-018.
[41] Ministry of Health, Labour and Welfare. National Database of Health Insurance Claims and Specific Health Checkups of Japan [EB/OL]. [2022-05-05]. https://www.mhlw./stf/seisakunitsuite/bunya/0000177221_000 10.html. In Japanese.
[42] 孔祥前, 高记华, 孙少哲, 等. 矾藤痔硬化剂注射治疗Ⅰ~Ⅱ度内痔的临床疗效观察[J]. 结直肠肛门外科, 2022,28(6):588- 592. DOI:10.19668/j.cnki.issn1674-0491.2022.06.013.
[43] 高记华, 张虹玺. 矾藤痔注射疗法专家共识[J]. 中医临床研究, 2018, 10(15):106-107. DOI:10.3969/j.issn.1674-7860. 2018.15.048.
[44] 韩滨泽, 杨铁军, 何瑾. 矾藤痔注射液注射法与胶圈套扎法治疗各期痔疮的疗效对比观察[J].中国临床新医学, 2019,12(2):179-182. DOI:10.3969/j.issn.1674-3806.2019. 02.16.
[45] 张串串,张相安. 矾藤痔注射液治疗Ⅰ、Ⅱ期内痔40例临床观察[J].中医临床研究,2018, 10(24): 40-41. DOI:CNKI:SUN:ZYLY.0.2018-24-022.
[46] 鲁明良, 鲁施菲尔, 韩滨泽. 基于中医固脱理论的矾藤痔治疗痔病临床疗效评价[J]. 成都中医药大学学报, 2022,45(3): 58-62. DOI:10.13593/j.cnki.51-1501/r.2022.03.058.
[47] 汪先忠. 无水乙醇治疗内痔18例[J]. 现代医药卫生, 2005, 21 (6):695-696. DOI:10.3969/j.issn.1009-5519.2005.06.060.
[48] 张成路. 外痔切除内痔套扎加75%酒精注射治疗混合痔120例疗效观察[J]. 中国肛肠病杂志, 2023,43(1):32. DOI:10.3969/j.issn.1000-1174.2023.01.013.
[49] 仇波, 王建中. 鱼肝油酸钠的应用与探讨[J].中国海洋药物, 2000,19(6):48-53. DOI:10. 3969/j.issn.1002-3461.2000. 06.014.
[50] 阳训武, 阳文飞, 侯翔. 自动痔疮套扎术联合鱼肝油酸钠注射治疗Ⅲ及Ⅳ期内痔200例疗效观察[J]. 中国社区医师, 2020,36(31):62-63. DOI:10.3969/j.issn.1007-614x.2020.31.030.
[51] 田强, 赵锦祥, 田中玉. 鱼肝油酸钠注射液注射治疗内痔2100例[J]. 实用乡村医生杂志, 2003,10(5):18. DOI:10.3969/j.issn. 1672-7185.2003.05.021.